• Principal Investigator
  • Male

Prof. dr. A.P. Kater MD PhD

Position:
Main activities: Patient care, Research, Teaching
Specialisation:
foto A.P. Kater is one of the AMC Principal Investigators
Focus of research:

Research focus on biology and treatment of B-cell malignancies with chronic lymphocytic leukemia (CLL) as main disease serving as a B-cell malignancy model.

Research involves both pre-clinical (cellines, primary CLL cells, mouse models) as well as clinical (phase 1, 2, 3) studies.

The studies are divided in three reserach programs around the central theme: development of, circumvention of and novel strategies for (development of) chemorefractory disease

1. Genetic abberations

2. Intracellular signaling

3. Cross-talk with microenvironment

AMC themes: Infection & Immunity, Oncology
Departments: Experimental Immunology, Internal Medicine: Clinical Haematology
de Weerdt I, Koopmans SM, Kater AP, van Gelder M, Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. HAEMATOLOGICA 2017;102 (10):1629-1639 [PubMed]
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M, Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. LANCET HAEMATOL 2017;4 (10):E475-E486 [PubMed]
Singh SP, Pillai SY, de Bruijn MJW, Stadhouders R, Corneth OBJ, van den Ham HJ, Muggen A, van Ijcken W, Slinger E, Kuil A, Spaargaren M, Kater AP, Langerak AW, Hendriks RW, Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. ONCOTARGET 2017;8 (42):71981-71995 [PubMed]
Slinger E, Thijssen R, Kater AP , Eldering E, Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. LEUKEMIA 2017;-:- [PubMed]
van Attekum MHA. Formation of a tumor-supportive microenvironment in chronic lymphocytic leukemia: Addressing the reciprocal interactions in the CLL—T cell—macrophage triad. S.l.: s.n.; 2017. 160p. ISBN 978-94-6182-754-8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): )
van Attekum MHA, Eldering E, Kater AP, Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. HAEMATOLOGICA 2017;102 (9):1469-1476 [PubMed]
van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP , Eldering E, Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. ONCOGENE 2017;36 (26):3651-3660 [PubMed]
van Attekum MHA, van Bruggen JAC, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP, CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. HAEMATOLOGICA 2017;ahead of print [PubMed]
van der Valk M, Zaaijer HL, Kater AP, Schinkel J, Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J HEPATOL 2017;66 (1):242-243 [PubMed]
de Weerdt I, van Hoeven V, Munneke JM, Endstra S, Hofland T, Hazenberg MD, Kater AP, Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. HAEMATOLOGICA 2016;101 (11):E461-E464 [PubMed]
Heijink DM, Kater AP , Hazenberg MD, Hagenbeek A, Kersten MJ, T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. NETH J MED 2016;74 (4):147-151 [PubMed]
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP , Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P, A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. LEUKEMIA 2016;30 (4):929-936 [PubMed]
Siska PJ, van der Windt GJW, Kishton RJ, Cohen S, Eisner W, MacIver NJ, Kater AP, Weinberg JB, Rathmell JC, Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. J IMMUNOL 2016;197 (6):2532-2540 [PubMed]
Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E, Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. HAEMATOLOGICA 2016;101 (9):e376-e377 [PubMed]
Stevens WBC, Netea MG, Kater AP, van der Velden WJFM, 'Trained immunity': consequences for lymphoid malignancies. HAEMATOLOGICA 2016;101 (12):1460-1468 [PubMed]
te Raa GD, Kater AP, TP53 dysfunction in CLL: Implications for prognosis and treatment. BEST PRACT RES CL HA 2016;29 (1):90-99 [PubMed]
Thijssen R. The interplay between microenvironmental signaling and novel targeted drugs in CLL. S.l.: s.n.; 2016. 171p. ISBN 978-94-6182-733-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): Kersten MJ)
Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016). LEUKEMIA 2016;30 (9):1963 [PubMed]
van Attekum MHA, Kater AP , Eldering E, The APRIL paradox in normal versus malignant B cell biology. CELL DEATH DIS 2016;7 (6):e2276 [PubMed]
van Attekum MHA, Terpstra S, Reinen E, Kater AP , Eldering E, Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling. CELL DEATH DISCOV 2016;2:16020 [PubMed]
van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MCJ, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP, Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. BONE MARROW TRANSPL 2016;51 (6):799-806 [PubMed]
[Contributors: Kersting S, Levin MD, Chamuleau M, Daenen SMGJ, Dompeling EC, Doorduijn JK, van Gelder M, Hoogendoorn M, Kerst JM, Nijland M, Nijziel MR, Posthuma EFM, Raymakers RAP, Schaafsma MR, Silbermann MH, van der Straaten HM, Veelken JH, Vos JMI, Wittebol S, van Oers MHJ, Kater AP]] , Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia. NETH J MED 2016;74 (2):68-74 [PubMed]
Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, Dietrich S, Oakes CC, Dreger P, te Raa D, Kater AP , Jauch A, Merkel O, Oren M, Hielscher T, Zenz T, p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. LEUKEMIA 2015;29 (10):2015-2023 [PubMed]
de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M, Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. BLOOD 2015;125 (14):2306-2309 [PubMed]
Kater AP, Lanasa MC, Wesselmann J, Fischer K, The 8th Young Investigators' Meeting on Chronic Lymphocytic Leukemia. LEUKEMIA LYMPHOMA 2015;56 (5):1556-1559 [PubMed]
Kater AP, van der Windt GJW, PD-L1 blockade: rejuvenating T cells in CLL. BLOOD 2015;126 (2):126-128 [PubMed]
Spaargaren M, de Rooij MFM, Kater AP , Eldering E, BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. ONCOGENE 2015;34 (19):2426-2436 [PubMed]
te Raa GD. Molecular characteristics and prognosis in CLL. S.l.: s.n.; 2015. 240p. ISBN 978-94-6182-531-5 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Eldering EF; copromotor(s): Kater AP)
te Raa GD, Derks IAM, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MHJ, Kater AP , Eldering E, The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 2015;29 (5):1133-1142 [PubMed]
te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP, Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. CELL DEATH DIS 2015;6:e1852 [PubMed]
Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. HAEMATOLOGICA 2015;100 (8):e302-e306 [PubMed]
Tonino SH, Mulkens CE, van Laar J, Derks IAM, Suo G, Croon-de Boer F, van Oers MHJ, Eldering E, Wang JY, Kater AP, Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2015;56 (8):2439-2447 [PubMed]
Kater AP, Eldering E, miR in CLL: more than mere markers of prognosis?. BLOOD 2014;124 (1):2-4 [PubMed]
Kater AP, Spiering M, Liu RD, Doreen te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NAG, Luijks DM, Eldering E, van Oers MHJ, Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. LEUKEMIA RES 2014;38 (1):34-41 [PubMed]
Kater AP, Tonino SH, Egle A, Ramsay AG, How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. BLOOD 2014;124 (14):2184-2189 [PubMed]
Lim KH, Thomas G, van Beers EJ, Hosman AE, Mourits MP, van Noesel CJM, Kater AP , Reinartz SM, Acute sinusitis and blindness as the first presentation of chronic lymphocytic leukaemia. NETH J MED 2014;72 (10):548-550 [PubMed]
te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRIT J HAEMATOL 2014;167 (4):565-569 [PubMed]
te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EBM, ten Berge IJM, van Lier RAW, Eldering E, van Oers MHJ, Tonino SH, Kater AP, CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia. BLOOD 2014;123 (5):717-724 [PubMed]
de Weerdt I, Eldering E, van Oers MH, Kater AP, The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. LEUKEMIA RES 2013;37 (7):838-847 [PubMed]
Hoogeboom R, van Kessel KPM, Hochstenbach F, Wormhoudt TA, Reinten RJA, Wagner K, Kater AP, Guikema JEJ, Bende RJ, van Noesel CJM, A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J EXP MED 2013;210 (1):59-70 [PubMed]
Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T, Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. BRIT J HAEMATOL 2013;163 (4):496-500 [PubMed]
Kater AP, The half-life of guidelines for Waldenstrom's macroglobulinaemia; short stickiness for a sticky disease?. NETH J MED 2013;71 (2):52-53 [PubMed]
Lanasa MC, Kater AP, Shanafelt T, Fischer K, Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2013;54 (8):1815-1816 [PubMed]
Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JEJ, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MHJ, Eldering E, Medema JP, Kater AP, Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. BLOOD 2013;122 (24):3960-3963 [PubMed]
Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP , Griffioen M, Spierings E, Lokhorst HM, Mutis T, Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. LEUKEMIA 2013;27 (3):642-649 [PubMed]
Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, van Attekum MHA, van Bochove GG, Luijks DM, Pals ST, van Lier RAW, Kater AP, van Oers MHJ, Eldering E, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. BLOOD 2013;122 (17):3010-3019 [PubMed]
te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2013;54 (8):1849-1853 [PubMed]
van den Broek EC, Kater AP , van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF, Chronische lymfatische leukemie in Nederland: Trends in incidentie, behandeling en overleving (1989-2008). NED TIJDSCHR HEMATOL 2013;10:244-253
Kater AP , Chamuleau ME, Posthuma W, Schipperus MR, Spiering M, van Oers MH, HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patienten en patienten met comorbiditeit; een fase I/II-studie. NED TIJDSCHR HEMATOL 2012;9:197
Kater AP, Shanafelt T, Fischer K, Wierda W, Highlights of the 6th Young Investigators' Meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2012;53 (11):2312-2313 [PubMed]
Lapid O, van der Horst CM, Kater AP, Donor-Derived Fat Tissue As a Source for Lipofilling After Allogeneic Hematopoietic Cell Transplantation. J CLIN ONCOL 2012;30 (17):E154-E155 [PubMed]
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP , Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. LEUKEMIA 2012;26 (7):1458-1461 [PubMed]
te Raa GD, Tonino SH, Remmerswaal EBM, van Houte AJ, Koene HR, van Oers MH, Kater AP, Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. LEUKEMIA LYMPHOMA 2012;53 (11):2321-2325 [PubMed]
te Raa GD, van Oers MH, Kater AP, Monoclonal B-cell lymphocytosis: Recommendations from the Dutch Working Group on CLL for daily practice. NETH J MED 2012;70 (5):236-241 [PubMed]
te Raa GD, van Oers MH, Kater AP, Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk. NED TIJDSCHR HEMATOL 2012;9:138
Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RAW, van Oers MH, Kater AP, Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2012;53 (9):1785-1794 [PubMed]
Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MHJ, Eldering E, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. CLIN CANCER RES 2012;18 (2):487-498 [PubMed]
van den Broek EC, Kater AP , van de Schans SAM, Karim-Kos HE, Janssen-Heijnen MLG, Peters WG, Nooijen PTGA, Coebergh JWW, Posthuma EFM, Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008. EUR J CANCER 2012;48 (6):889-895 [PubMed]
Fischer K, Shanafelt T, Kater AP, Highlights of the 5th Young Investigators' Meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2011;52 (7):1391-1393 [PubMed]
Guadagnoli M, Kimberley F, Phan U, Cameron K, Vink P, Rodermond H, Eldering E, Kater A, van Eenennaam H, Medema JP, Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. BLOOD 2011;117 (25):6856-6865 [PubMed]
Kater AP, CLL: Nu werken aan behandeling van de toekomst. HEMATOL NEWS INT 2011;5 (6):21-23
Kater AP, Voor welke patiënten wordt ofatumumab vergoed?. HEMATOLOGIE ACTUEEL 2011;11 (5):onbekend
Kater AP , Wittebol S, Chamuleau MED, van Gelder M, J van Oers MH, Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. NETH J MED 2011;69 (10):422-429 [PubMed]
Kater AP , Wittebol S, Chamuleau ME, van Gelder M, van Oers MH, Richtlijnen diagnostiek en behandeling chronische lymfatische leukemie 2011. NED TIJDSCHR HEMATOL 2011;8:190-201
Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater AP, Mertens D, te Raa D, Döhner H, Stilgenbauer S, Zenz T, DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. BLOOD 2011;117 (5):1622-1632 [PubMed]
te Raa GD, Fischer K, Verweij W, van Houte AJ, Kater AP, Biesma DH, Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. CLIN CHEM LAB MED 2011;49 (1):115-120 [PubMed]
Tonino SH. Targets for the treatment of drug resistant chronic lymphocytic leukemia. s.l.: s.n.; 2011. 175p. ISBN 9789090264820 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Kater AP , Eldering E)
Tonino SH, Rijssenbeek AL, Oud ME, Pals ST, van Oers MH, Kater AP, Intracerebral Infiltration As the Unique Cause of the Clinical Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. J CLIN ONCOL 2011;29 (34):E837-E839 [PubMed]
Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP, ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. ONCOGENE 2011;30 (6):701-713 [PubMed]
Vos JMI, Bordbar A, Vet R, Pals ST, Kater AP, Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. LEUKEMIA LYMPHOMA 2011;52 (4):705-708 [PubMed]
Kater AP, Tonino SH, Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study. CL LYMPH MYELOM LEUK 2010;10 (Suppl. 1):S34-S41 [PubMed]
Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP, R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. LEUKEMIA 2010;24 (3):652-654 [PubMed]
Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP , van Lier RAW, van Oers MHJ, Eldering E, Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. ONCOGENE 2010;29 (36):5071-5082 [PubMed]
Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ, B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. P NATL ACAD SCI USA 2010;107 (44):18956-18960 [PubMed]
Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ, Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. BLOOD 2009;114 (20):4469-4476 [PubMed]
Kater AP , van Oers MHJ, De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie. NED TIJDSCHR HEMATOL 2009;6 (8):317-320
Mous R, Jaspers A, Luijks DMP, Mellink CHM, van Oers MHJ, Kater AP , Eldering E, Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. LEUKEMIA 2009;23 (7):1352-1355 [PubMed]
Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MHJ, Mertens D, Döhner H, Stilgenbauer S, miR-34a as part of the resistance network in chronic lymphocytic leukemia. BLOOD 2009;113 (16):3801-3808 [PubMed]
Choi G, van den Borne MPJ, Visser CE, Kersten MJ, Kater AP, Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. ANN HEMATOL 2008;87 (9):771-772 [PubMed]
Hallaert DYH, Jaspers A, van Noesel CJ, van Oers MHJ, Kater AP, Eldering E, c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. BLOOD 2008;112 (13):5141-5149 [PubMed]
Kater AP , van Oers MHJ, De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie. NED TIJDSCHR HEMATOL 2008;5 (6):236-244
Sonke GS, Ludwig I, van Oosten H, Baars JW, Meijer E, Kater AP, de Jong D, Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. CLIN INFECT DIS 2008;47 (1):105-108 [PubMed]
Tonino SH, Spijker R, Luijks DMP, van Oers MHJ, Kater AP, No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. BLOOD 2008;112 (3):840-843 [PubMed]
van Dam IE, Kater AP , Hart W, van den Born BJH, Ernstige anemie door infectie met het Humaan parvovirus B19 bij een patiënt met een auto-immuun-hemolytische anemie en een B-cel-non-hodgkinlymfoom. NED TIJDSCHR GENEESKD 2008;152 (3):153-157 [PubMed]
van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F, In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. CANCER RES 2008;68 (24):10137-10144 [PubMed]
Bouw J, Kater AP, van Tongeren J, Schultz MJ, Upper-airway obstruction instigated by Sweet's syndrome. MED SCI MONITOR 2007;13 (4):CS53-CS55 [PubMed]
Kater A, Henke MO, Rubin BK, The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. ANN NY ACAD SCI 2007;1112:140-153 [PubMed]
Kater AP, van Oers MHJ, Kipps TJ, Cellular immune therapy for chronic lymphocytic leukemia. BLOOD 2007;110 (8):2811-2818 [PubMed]
Smit LA, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MHJ, van Noesel CJM, Eldering E, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. BLOOD 2007;109 (4):1660-1668 [PubMed]
Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ, CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. BLOOD 2006;108 (10):3450-3457 [PubMed]
Kater AP. Novel apoptosis inducting strategies in chronic lymphocytic leukemia. S.l.: s.n.; 2006. 208p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Kipps TJ; copromotor(s): Eldering E)
Rubin BK, Kater AP, Goldstein AL, Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. CHEST 2006;130 (5):1433-1440 [PubMed]
Dicker F, Kater AP, Fukuda T, Kipps TJ, Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. BLOOD 2005;105 (8):3193-3198 [PubMed]
Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ, Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. BLOOD 2005;106 (5):1742-1748 [PubMed]
Kater AP , van Oers MHJ. Chronic lymphocytic leukemia: time for a risk-adapted approach in: Romero RM, editors. Trends in leukemia research. S.l.: Nova Science Publishers, Inc; 2005., p. 363-383
Mackus WJM, Kater AP , Grummels A, Evers LM, Hooijbrink B, Kramer MHH, Castro JE, Kipps TJ, van Lier RAW, van Oers MHJ, Eldering E, Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. LEUKEMIA 2005;19 (3):427-434 [PubMed]
Kater AP, Evers LM, Remmerswaal EBM, Jaspers A, Oosterwijk MF, van Lier RAW, van Oers MHJ, Eldering E, CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. BRIT J HAEMATOL 2004;127 (4):404-415 [PubMed]
Kater AP, Remmerswaal EBM, Nolte MA, Eldering E, van Oers MHJ, van Lier RAW, Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. BRIT J HAEMATOL 2004;126 (4):512-516 [PubMed]
Kater AP , van Oers MHJ, Chronische lymfatische leukemie: hoog tijd voor een op het risico afgestemd beleid. NED TIJDSCHR GENEESKD 2003;147 (3):104-110 [PubMed]
Kater AP, Peppelenbosch MP, Brandjes DPM, Lumbantobing M, Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. CLIN DIAGN LAB IMMUN 2002;9 (6):1396-1397 [PubMed]
Kater AP , van der Lelie J, Levi M, Trombotische microangiopathie: trombocytopenie en hemolytische anemie. NED TIJDSCHR GENEESKD 2002;146 (49):2343-2347 [PubMed]
Kater AP , van Oers MHJ, Immunogentherapie. Bestrijding leukemie door activatie afweersysteem met behulp van CD70. ANALYSE (AMSTERDAM) 2002;- (oktober):240-242
Schnog JB, Kater AP , Mac Gillavry MR, Duits AJ, Lard LR, van der Dijs FP, Brandjes DP, ten Cate H, van Eps LW, Rojer RA, Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. AM J HEMATOL 2001;68 (3):179-183 [PubMed]
Kater AP , Westermann AM , de Groot MR, von dem Borne AE, Kuijper EJ, Toxin-mediated haemolytic uraemic syndrome without diarrhoea. J INTERN MED 2000;248 (3):263-265 [PubMed]
Kater AP , Heijboer H, Peters M, Vogels T, Prins MH, Heymans HS, Kwaliteit van leven bij kinderen met sikkelcelziekte in de regio Amsterdam. NED TIJDSCHR GENEESKD 1999;143 (41):2049-2053 [PubMed]
Kater AP , Prins MH, von Rosenstiel IA, Ottenkamp J, Peters M, Transient thrombocytopenia after cardiac surgery in infants with Down syndrome. J PEDIAT HEMATOL ONC 1999;21 (2):170-171 [PubMed]
Key publications

Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP, Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. CELL DEATH DIS 2015;6:e1852 [PubMed]
te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EBM, ten Berge IJM, van Lier RAW, Eldering E, van Oers MHJ, Tonino SH, Kater AP, CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia. BLOOD 2014;123 (5):717-724 [PubMed]
Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JEJ, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MHJ, Eldering E, Medema JP, Kater AP, Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. BLOOD 2013;122 (24):3960-3963 [PubMed]


All Publications

Curriculum Vitae

Biographical sketch
Title(s): MD, PhD (dr.)
Name: Arnon (Aron) Philip Kater
Sex: Male
Date and place of birth: 22 October 1972, Amsterdam, the Netherlands Marital state: Married, 2 children

Master’s
University: University of Amsterdam
Date: 01 October 1995
Main Subject: Medicine (cum laude)
Doctorate
University: University of Amsterdam
Date: 02 February 2006
Supervisor/ Promotor: prof. dr. M. H. van Oers
Title of Thesis: Live and let die; Novel apoptosis inducing strategies in chronic lymphocytic leukemia

Professional/work experience
1992 - 1993: Research assistant Lab. Exp. Dermatology, Academic Medical Center (AMC), Amsterdam
1994: Teaching Assistant, Department of Physiology, Faculty of Medicine, University of Amsterdam.
1994: Scientific Research Placement, Department of Biochemistry and Molecular Biology, the George Washington University, Washington DC & Laboratory of Experimental Pulmonology, St. Louis University, St. Louis, Missouri, USA
1998: Voluntary Scientific Research Placement, Dept. of Pediatric Hematology, Emma Children Hospital, Amsterdam
1998 - 1999: Voluntary Scientific Research Placement, Laboratory of Experimental Medicine, AMC
1998 - 2000: Voluntary Scientific Research Placement, Dept of Internal Medicine, Slotervaart hospital in collaboration with St. Elisabeth hospital, Willemstad, Curacao
1999 - 2003: Residency Internal Medicine; AMC and Slotervaart Municipal hospital, Amsterdam;
From 2003: “AGIKO” Medical Doctor in research / clinical research fellow (special version of PhD for MD)
2003 - 2004: PhD student / clinical research fellow, Lab. Of Experimental Immunology, AMC, Amsterdam
2004 - 2005: PhD student / clinical research fellow, Dept. Hematology-Oncology, University of California San Diego, La Jolla, CA, USA
2006: Thesis: Live and let die; Novel apoptosis inducing strategies in chronic lymphocytic leukemia
Oct 2006: Registration as Internist
2006 - 2007: Fellowship Clinical Hematology, Dept. of Internal Medicine, Division of hematology, AMC
Oct 2007: Registration as Hematologist
2007 - present: Member of staff, Department of Internal Medicine, Division of Hematology, AMC
2008 - 2009: Post-doctoral research, Moores Cancer Centre and the Laboratory of Gene Regulation and Signal Transduction, University of California San Diego, CA, USA (as part of NWO-VENI grant)
2010: Group leader of the Hematology group at the laboratory of Experimental Medicine
2012: Appointed as Principal Investigator of the AMC

 


International academic activities

A. MEMBERSHIPS:
• European Research Initiative on CLL (ERIC)
• American Society of Hematology

B. PRESENT INTERNATIONAL ACTIVITIES:
• Research:
o Coordinator European Leukemia Net /ERIC p53-function analysis CLL
o Active research collaboration with international grous; most intense with: dr. T. Zenz (University of Heidelberg, Germany); prof. dr. T. Stankovic (University of Birmingham, UK); dr. M. Lanasa (Duke University Medical Center, Durham NC); prof. dr. T.J. Kipps and prof. dr. M. Karin (University of California San Diego, la Jolla, CA)
• Conferences/committees
o Elected member of the Young Investigator Meeting committee of the International Workshop of CLL (2010, 2011, 2012, 2013)
o Chairman CLL biology session, European Haematology Assocation annual congress (2011)
o Abstract review committee CLL biology section, American Society of Hematology annual congress (2012)
o International Scientific Advisory Board member of the of the Central European Institute of Technology (CEITEC), Brno, Czech Republic on behalf of the European Union (2012 - present)


Other academic activities
A. TEACHING / SUPERVISION:
• (Co-)groupleader/PI of a translational research group consisting of 4 technicians, 5 PhD students and 3 post-docs
• Local, national and international hematology courses (see also E.)
• Local teaching/supervision hematology fellowship program AMC

B. COMMITTEES / STEERING GROUPS:
• Member HOVON CLL working group
• Member steering board HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)
• Member of the AMC VENI-support committee

C. CLINICAL TRIALS:
• Principal Investigator both HOVON/LLPC industry sponsored phase 1/2 trials as well as Principal Investigator of an investigator sponsored National HOVON/CLL working group phase 2 trial, National Principal Investigator of a investigator sponsored pan-European German CLL group/HOVON phase 3 trial, and member of global steering board and National Principal Investigator of an industry sponsored global phase 3 trial.


D. REVIEW / EDITORIAL WORK:
• Associated Editor Nederlands Tijdschrift voor Hematologie (Dutch Journal of Haematology)
• Regular reviewer: Blood, British Journal of Haematology, Leukemia, Haematologica, Leukemia & Lymphoma
• Grant reviewer: Dutch Cancer Foundation, UK Lymphoma and Leukemia Research foundation


E. INVITED LECTURES PAST THREE YEARS:
• Multiple lectures at national meetings as well as lectures at the University of Freiburg, the University of Brno, University of Heidelberg, United kingdom National translational CLL meeting, International Workshop of CLL meeting

F. INTERNATIONAL ADVISORY BOARDS PHARMACEUTICAL COMPANIES
• Roche, Johnson & Johnson, Celgene


Non-academic activities
‘07 - present Nederlands Israelitische instelling voor socaiel arbeid
Member of the board

’09 - present Vereniging Centrale Israelitische Ziekenverpleging (CIZ)
President/Chairman of the board; The CIZ is the only remaining jewish hospital in Europe. It was integrated in the early eighties with the Nicolaas Tulp hospital to form the current ziekenhuis Amstelland in Amstelveen. The jewish wing and the jewish identity of the hospital as a whole is the responsibility of the Vereniging CIZ.

Awards
1994 Hippocrates Award
National scientific award for best Dutch student investigator in the field of Medicine
1994 prof. dr. Ph.H. Quanjer Award
Annual student award for best research project supported by the Dutch Asthma Foundation
2004 American Society of Hematology Travel Award
Abstract award for resident physicians
2006 Van Vlissingen Foundation Junior Prize
Award from the van Vlissingen foundation for best thesis in the field of lymphoproliferative diseases in the Netherlands over the last three years; €2000
2007 Jan Swammerdam Award
Award from the Dutch Society of Hematology for most talented hematologist under the age of 45 in the Netherlands; €40.000
2007 van Leeuwen Stipendium
Personal award from the Ruitinga van Swieten foundation for top internists to perform research abroad; €20.000
2011 Dutch Cancer Society Clinical Cancer Research Award
Personal award for clinicians active in oncology/hematology in order to develop their
own research group; €800.000

Grants
1994 Dutch Asthma Foundation student grant and
Dutch Cystic Fibrosis Foundation grant
2002 Dutch Cancer Society research year for residents
Personal grant to perform one year of research during residency; one-year salary and bench-fee
2003 Rene Vogels Foundation travel grant
Personal grant in order to perform research at the University of California San-Diego, USA; €10.000
2004 Dutch Cancer Society Research grant for academics
Personal grant in order to perform research at the University of California San-Diego, USA; living expenses
2007 NWO VENI grant
Personal grant in order to initiate post doctoral studies. This grant was matched by the AMC which enabled me to supervise my first PhD student; NWO €208.000
2009 Dutch Cancer Society project grant; €500.000
2009 Genzyme Europe BV. Research grant; €40.000
2009 Peter vd Laan foundation research grant; €142.750
2009 University of Amsterdam Parelsnoer Research grant; €142.750
2009 Hoffmann-La Roche Ltd research grant; €20.000
2010 Dutch Leukemia foundation research grant; €30.000
2010 Celgene Biopharmaceutical Corporation Clinical and translational research grant; €278.000
2011 Hoffmann-La Roche Ltd research grant; €63.000
2012 Sanofi Aventis Oncology research grant; €80.000
2012 Celgene Biopharmaceutical Corporation basic research grant; €80.000
2012 Dutch Leukemia foundation research grant; €50.000


Publications
International peer-reviewed
1. Kater,A.P., Prins,M.H., von Rosenstiel,I.A., Ottenkamp,J., and Peters,M., Transient thrombocytopenia after cardiac surgery in infants with Down syndrome. J.Pediatr.Hematol.Oncol. 1999. 21: 170-171.
2. Kater,A.P., Heijboer,H., Peters,M., Vogels,T., Prins,M.H., and Heymans,H.S., [Quality of life in children with sickle cell disease in Amsterdam area]. Ned.Tijdschr.Geneeskd. 1999. 143: 2049-2053.
3. Kater,A.P., Westermann,A.M., de Groot,M.R., von dem Borne,A.E., and Kuijper,E.J., Toxin-mediated haemolytic uraemic syndrome without diarrhoea. J.Intern.Med. 2000. 248: 263-265.
4. Schnog,J.B., Kater,A.P., Mac Gillavry,M.R., Duits,A.J., Lard,L.R., van Der Dijs,F.P., Brandjes,D.P., ten,C.H., van Eps,L.W., and Rojer,R.A., Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am.J.Hematol. 2001. 68: 179-183.
5. Kater,A.P., van der Lelie,J., and Levi,M., [Thrombotic microangiopathy: thrombocytopenia and hemolytic anemia]. Ned.Tijdschr.Geneeskd. 2002. 146: 2343-2347.
6. Kater,A.P., Peppelenbosch,M.P., Brandjes,D.P., and Lumbantobing,M., Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. Clin.Diagn.Lab Immunol. 2002. 9: 1396-1397.
7. Kater,A.P. and van Oers,M.H., [Chronic lymphocytic leukemia: high time for a risk-adapted approach]. Ned.Tijdschr.Geneeskd. 2003. 147: 104-109.
8. Kater,A.P., Remmerswaal,E.B., Nolte,M.A., Eldering,E., van Oers,M.H., and van Lier,R.A., Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br.J.Haematol. 2004. 126: 512-516.
9. Kater,A.P., Evers,L.M., Remmerswaal,E.B., Jaspers,A., Oosterwijk,M.F., van Lier,R.A., van Oers,M.H., and Eldering,E., CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br.J.Haematol. 2004. 127: 404-415.
10. Dicker,F., Kater,A.P., Fukuda,T., and Kipps,T.J., Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 2005. 105: 3193-3198.
11. Kater,A.P., Dicker,F., Mangiola,M., Welsh,K., Houghten,R., Ostresh,J., Nefzi,A., Reed,J.C., Pinilla,C., and Kipps,T.J., Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005. 106: 1742-1748.
12. Mackus,W.J., Kater,A.P., Grummels,A., Evers,L.M., Hooijbrink,B., Kramer,M.H., Castro,J.E., Kipps,T.J., van Lier,R.A., van Oers,M.H., and Eldering,E., Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005. 19: 427-434.
13. Dicker,F., Kater,A.P., Prada,C.E., Fukuda,T., Castro,J.E., Sun,G., Wang,J.Y., and Kipps,T.J., CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006. 108: 3450-3457.
14. Rubin,B.K., Kater,A.P., and Goldstein,A.L., Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006. 130: 1433-1440.
15. Bouw,J., Kater,A.P., van,T.J., and Schultz,M.J., Upper-airway obstruction instigated by Sweet's syndrome. Med.Sci.Monit. 2007. 13: CS53-CS55.
16. Kater,A., Henke,M.O., and Rubin,B.K., The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. Ann.N.Y.Acad.Sci. 2007. 1112: 140-153.
17. Kater,A.P., van Oers,M.H., and Kipps,T.J., Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007. 110: 2811-2818.
18. Smit,L.A., Hallaert,D.Y., Spijker,R., de,G.B., Jaspers,A., Kater,A.P., van Oers,M.H., van Noesel,C.J., and Eldering,E., Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007. 109: 1660-1668.
19. Choi,G., van den Borne,M.P., Visser,C.E., Kersten,M.J., and Kater,A.P., Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. Ann.Hematol. 2008. 87: 771-772.
20. Hallaert,D.Y., Jaspers,A., van Noesel,C.J., van Oers,M.H., Kater,A.P., and Eldering,E., c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008. 112: 5141-5149.
21. Sonke,G.S., Ludwig,I., van,O.H., Baars,J.W., Meijer,E., Kater,A.P., and de,J.D., Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. Clin.Infect.Dis. 2008. 47: 105-108.
22. Tonino,S.H., Spijker,R., Luijks,D.M., van Oers,M.H., and Kater,A.P., No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood 2008. 112: 840-843.
23. van Dam,I.E., Kater,A.P., Hart,W., and van den Born,B.J., [Severe anaemia caused by Human Parvovirus B19 infection in a patient with autoimmune haemolytic anaemia and a B-cell non-Hodgkin lymphoma]. Ned.Tijdschr.Geneeskd. 2008. 152: 153-157.
24. van,G.R., Kater,A.P., Otto,S.A., Jaspers,A., Borghans,J.A., Vrisekoop,N., Ackermans,M.A., Ruiter,A.F., Wittebol,S., Eldering,E., van Oers,M.H., Tesselaar,K., Kersten,M.J., and Miedema,F., In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res. 2008. 68: 10137-10144.
25. Enzler,T., Kater,A.P., Zhang,W., Widhopf,G.F., Chuang,H.Y., Lee,J., Avery,E., Croce,C.M., Karin,M., and Kipps,T.J., Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009. 114: 4469-4476.
26. Mous,R., Jaspers,A., Luijks,D.M., Mellink,C.H., van Oers,M.H., Kater,A.P., and Eldering,E., Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009. 23: 1352-1355.
27. Zenz,T., Mohr,J., Eldering,E., Kater,A.P., Buhler,A., Kienle,D., Winkler,D., Durig,J., van Oers,M.H., Mertens,D., Dohner,H., and Stilgenbauer,S., miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009. 113: 3801-3808.
28. Kater,A.P. and Tonino,S.H., Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study. Clin.Lymphoma Myeloma.Leuk. 2010. 10 Suppl 1: S34-S41.
29. Tonino,S.H., van,G.M., Eldering,E., van Oers,M.H., and Kater,A.P., R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 2010. 24: 652-654.
30. Tromp,J.M., Tonino,S.H., Elias,J.A., Jaspers,A., Luijks,D.M., Kater,A.P., van Lier,R.A., van Oers,M.H., and Eldering,E., Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010. 29: 5071-5082.
31. Zhang,W., Kater,A.P., Widhopf,G.F., Chuang,H.Y., Enzler,T., James,D.F., Poustovoitov,M., Tseng,P.H., Janz,S., Hoh,C., Herschman,H., Karin,M., and Kipps,T.J., B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc.Natl.Acad.Sci.U.S.A 2010. 107: 18956-18960.
32. Fischer,K., Shanafelt,T., and Kater,A.P., Highlights of the 5th Young Investigators' Meeting on chronic lymphocytic leukemia. Leuk.Lymphoma 2011. 52: 1391-1393.
33. Guadagnoli,M., Kimberley,F.C., Phan,U., Cameron,K., Vink,P.M., Rodermond,H., Eldering,E., Kater,A.P., van,E.H., and Medema,J.P., Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 2011. 117: 6856-6865.
34. Kater,A.P., Wittebol,S., Chamuleau,M.E., van,G.M., Oers MH,J.v., and Hovon CLL,W.P., Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. Neth.J.Med. 2011. 69: 422-429.
35. Mohr,J., Helfrich,H., Fuge,M., Eldering,E., Buhler,A., Winkler,D., Volden,M., Kater,A.P., Mertens,D., Te,R.D., Dohner,H., Stilgenbauer,S., and Zenz,T., DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011. 117: 1622-1632.
36. Te Raa,G.D., Fischer,K., Verweij,W., van Houte,A.J., Kater,A.P., and Biesma,D.H., Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. Clin.Chem.Lab Med. 2011. 49: 115-120.
37. Tonino,S.H., van,L.J., van Oers,M.H., Wang,J.Y., Eldering,E., and Kater,A.P., ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 2011. 30: 701-713.
38. Tonino,S.H., Rijssenbeek,A.L., Oud,M.E., Pals,S.T., van Oers,M.H., and Kater,A.P., Intracerebral infiltration as the unique cause of the clinical presentation of chronic lymphocytic leukemia/small lymphocytic leukemia. J.Clin.Oncol. 2011. 29: e837-e839.
39. Vos,J.M., Bordbar,A., Vet,R.J., Pals,S.T., and Kater,A.P., Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. Leuk.Lymphoma 2011. 52: 705-708.
40. Lapid,O., van der Horst,C.M., and Kater,A.P., Donor-derived fat tissue as a source for lipofilling after allogeneic hematopoietic cell transplantation. J.Clin.Oncol. 2012. 30: e154-e155.
41. Pospisilova,S., Gonzalez,D., Malcikova,J., Trbusek,M., Rossi,D., Kater,A.P., Cymbalista,F., Eichhorst,B., Hallek,M., Dohner,H., Hillmen,P., van,O.M., Gribben,J., Ghia,P., Montserrat,E., Stilgenbauer,S., and Zenz,T., ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012. 26: 1458-1461.
42. Te Raa,G.D., Tonino,S.H., Remmerswaal,E.B., van Houte,A.J., Koene,H.R., van Oers,M.H., and Kater,A.P., Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. Leuk.Lymphoma 2012. 53: 2321-2325.
43. Te Raa,G.D., van Oers,M.H., and Kater,A.P., Monoclonal B-cell lymphocytosis: recommendations from the Dutch Working Group on CLL for daily practice. Neth.J.Med. 2012. 70: 236-241.
44. Tonino,S.H., van de Berg,P.J., Yong,S.L., Ten Berge,I.J., Kersten,M.J., van Lier,R.A., van Oers,M.H., and Kater,A.P., Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leuk.Lymphoma 2012. 53: 1785-1794.
45. Tromp,J.M., Geest,C.R., Breij,E.C., Elias,J.A., van,L.J., Luijks,D.M., Kater,A.P., Beaumont,T., van Oers,M.H., and Eldering,E., Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin.Cancer Res. 2012. 18: 487-498.
46. van den Broek,E.C., Kater,A.P., van de Schans,S.A., Karim-Kos,H.E., Janssen-Heijnen,M.L., Peters,W.G., Nooijen,P.T., Coebergh,J.W., and Posthuma,E.F., Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. Eur.J.Cancer 2012. 48: 889-895.
47. de,W., I, Eldering,E., van Oers,M.H., and Kater,A.P., The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leuk.Res. 2013. 37: 838-847.
48. Hoogeboom,R., van Kessel,K.P., Hochstenbach,F., Wormhoudt,T.A., Reinten,R.J., Wagner,K., Kater,A.P., Guikema,J.E., Bende,R.J., and van Noesel,C.J., A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J.Exp.Med. 2013. 210: 59-70.
49. Jethwa,A., Hullein,J., Stolz,T., Blume,C., Sellner,L., Jauch,A., Sill,M., Kater,A.P., Te Raa,G.D., Geisler,C., van,O.M., Dietrich,S., Dreger,P., Ho,A.D., Paruzynski,A., Schmidt,M., von,K.C., Glimm,H., and Zenz,T., Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br.J.Haematol. 2013. 163: 496-500.
50. Kater,A.P., The half-life of guidelines for Waldenstrom's macroglobulinaemia; short stickiness for a sticky disease? Neth.J.Med. 2013. 71: 52-53.
51. Kater,A.P., Spiering,M., Liu,R.D., Doreen Te,R.G., Slinger,E., Tonino,S.H., Beckers,M.M., Daenen,S., Doorduijn,J.K., Lankheet,N.A., Luijks,D.M., Eldering,E., and van Oers,M.H., Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leuk.Res. 2013.
52. Lanasa,M.C., Kater,A.P., Shanafelt,T., and Fischer,K., Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia. Leuk.Lymphoma 2013. 54: 1815-1816.
53. Lascano,V., Guadagnoli,M., Schot,J.G., Luijks,D.M., Guikema,J.E., Cameron,K., Hahne,M., Pals,S., Slinger,E., Kipps,T.J., van Oers,M.H., Eldering,E., Medema,J.P., and Kater,A.P., Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood 2013. 122: 3960-3963.
54. Oostvogels,R., Minnema,M.C., van,E.M., Spaapen,R.M., Te Raa,G.D., Giovannone,B., Buijs,A., van,B.D., Kater,A.P., Griffioen,M., Spierings,E., Lokhorst,H.M., and Mutis,T., Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia 2013. 27: 642-649.
55. Pascutti,M.F., Jak,M., Tromp,J.M., Derks,I.A., Remmerswaal,E.B., Thijssen,R., van Attekum,M.H., van Bochove,G.G., Luijks,D.M., Pals,S.T., van Lier,R.A., Kater,A.P., van Oers,M.H., and Eldering,E., IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013. 122: 3010-3019.
56. Te Raa,G.D., Malcikova,J., Pospisilova,S., Trbusek,M., Mraz,M., Garff-Tavernier,M.L., Merle-Beral,H., Lin,K., Pettitt,A.R., Merkel,O., Stankovic,T., van Oers,M.H., Eldering,E., Stilgenbauer,S., Zenz,T., and Kater,A.P., Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk.Lymphoma 2013. 54: 1849-1853.
57. Te Raa,G.D., Pascutti,M.F., Garcia-Vallejo,J.J., Reinen,E., Remmerswaal,E.B., Ten Berge,I.J., van Lier,R.A., Eldering,E., van Oers,M.H., Tonino,S.H., and Kater,A.P., CMV-specific CD8+ T cell function is not impaired in chronic lymphocytic leukemia. Blood 2013.

 


National/Dutch peer-reviewed
Kater,A.P., Heijboer,H., Peters,M., Vogels,T., Prins,M.H., and Heymans,H.S., [Quality of life in children with sickle cell disease in Amsterdam area]. Ned.Tijdschr.Geneeskd. 1999. 143: 2049-2053.
Kater,A.P., van der Lelie,J., and Levi,M., [Thrombotic microangiopathy: thrombocytopenia and hemolytic anemia]. Ned.Tijdschr.Geneeskd. 2002. 146: 2343-2347.
Kater,A.P. and van Oers,M.H., [Chronic lymphocytic leukemia: high time for a risk-adapted approach]. Ned.Tijdschr.Geneeskd. 2003. 147: 104-109.
Kater,A.P., Nieuwe apoptose-inducerende strategieën bij chronische lymfatische leukemie. Ned. Tijdschr. Hemat. 2007;4:77-80.
van Dam,I.E., Kater,A.P., Hart,W., and van den Born,B.J., [Severe anaemia caused by Human Parvovirus B19 infection in a patient with autoimmune haemolytic anaemia and a B-cell non-Hodgkin lymphoma]. Ned.Tijdschr.Geneeskd. 2008. 152: 153-157.
Kater, A.P., Van Oers, M.H., De tyrosinekinaseremmer Dasatinib voor behandeling van chemotherapie refractaire chronische lymfatische leukemie: de D’ACCORD-studie. Ned. Tijdschr. Hemat. 2009;6:317-20.
Kater, A.P., Wittebol, S., Chamuleau, M.E., van Gelde,r M., van Oers, M.H. Richtlijnen diagnostiek en behandeling chronische lymfatische leukemie. Ned. Tijdschr. Hemat. 2011;8:190-201.

te Raa, G.D., van Oers, M.H., Kater, A.P. Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk. Ned. Tijdschr. Hemat.2012;9:138-46.

Kater, A.P., Chamuleau, M.E., Posthuma, W., Schipperus, M.R., Spiering, M., van Oers, M.H. HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patiënten en patiënten met comorbiditeit; een fase I/II-studie. Ned. Tijdschr. Hemat. 2012;9:197-201.

de Weerdt, I., Eldering, E.,van Oers, M.H., Kater, A.P. Nieuwe kinase remmers in chronische lymfatische leukemie verbreken de interactie met het micromilieu. Ned. Tijdschr. Hemat. 2013


Bookchapters
1. Trends in Leukemia Research, chapter on CLL; 2005
2. Leerboek immunohematologie, hoofdstuk CLL; 2013
3. Leerboek Hematologie, Hoofdstuk laaggradige lymfomen; 2014

 

 

Research programmes

development of, circumvention of and novel strategies for (development of) chemorefractory CLL

(I) DNA damage response
The DNA damage response axis plays a crucial role in chemoresistance in CLL, as indicated by the prognostic impact of deletions of 17p (locus of TP53) and 11q (locus of ATM). These deletions coincide with mutations in the remaining allele, although frequency, especially for ATM varies. Functional read-outs of the p53 axis are expected to add clinical relevant information on the actual DNA damage response. Currently, different p53 function analyses are being developed. These assays are either based on measurement of (i) RNA expression levels of a single gene (RT-PCRp21) or gene sets (RT-MLPA, currently further developed by us), or protein expression levels (FACSp53-p21) after DNA damage by irradiation or etoposide/nutlin exposition or (ii) gene expression levels at base-line (RT-PCR miR34a). Although all tests relate to p53 function, they provide different information regarding expected responses towards therapy. P53 function assays are of promise in predicting sensitivity to chemotherapeutic agents provided that robustness and clinical applicability is thoroughly studied. In 2011 I started a pilot project within the framework of the European Research initiative on CLL (ERIC) to perform detailed side-by-side analysis of available p53 functional assays in 5 different countries (UK, the Netherlands, Germany, Austria, France, and Czech Republic). This unique collaborative approach will continue the following years and will include (mechanistic) analysis of novel described genetic aberrations in the DNA damage pathway.
(II) Signaling and cross-talk with the microenvironment
In the pathobiology of chronic lymphocytic leukemia (CLL), the tumor microenvironment plays a pivotal role by providing stimuli for survival and proliferation. However, the relevant interactions are still ill-defined and not targeted by current "conventional" treatments. This may explain why, despite major therapeutic advances, B-cell malignancies like CLL still remain incurable. For targeted therapy to succeed, better understanding of the interactions between leukemic cells and their microenvironment is critical. A variety of external signals has been suggested to influence survival of CLL cells, including B cell receptor (BCR) activation, interleukins/chemokines and cellular contact. Yet, these assumptions are predominantly based on in vitro model systems. In the first comparative survey between lymph node (LN) proliferation centers and blood derived CLL cells, we observed striking differences in Bcl-2 family members which correlated with sensitivity to standard chemotherapeutics. Our recent preliminary in vitro data indicate that besides tonic B-cell receptor (BCR) triggering, TNF-receptor family mediated signaling could account for the observed changes. We have also found that besides receptor/ligand interactions, activation of specific kinases by these stimuli hold high promise for targeted intervention. TNF-receptor family ligands CD40L, BAFF and APRIL, purportedly expressed by activated T cells and/or Nurse-like cells in CLL LN, enhance survival at least partly by NF-κB signaling. No study has yet attempted to directly compare CD40L, BAFF and APRIL and the NF-κB signaling involved for their impact on CLL survival and drug sensitivity. In fact, compelling evidence of expression of these ligands in CLL derived LN tissue is lacking. Moreover, no study has yet attempted to dissect pro-survival effects of T cells versus NLC, in relation to TNF(R) and kinase signaling.
In order to turn these concepts into targeted clinical approaches, this program aims to fill the following gaps in knowledge: 1. which signals predominate within the CLL microenvironment to provide chemoresistance and proliferation, 2. what molecular and functional events occur following distinct TNF-receptor family member mediated signaling. 3. Which intracellular signaling pathways hold most promise for therapeutic intervention with emphasis on kinase (family) activation. In order to gather meaningful and clinical relevant results these questions will be addressed by integrated study of LN CLL biopsy specimens, in vitro model systems and in vivo mouse models.
In addition, impact of novel drugs targeting the microenvironment will be addressed by phase 1, 2 and 3 clinical studies in CLL patients of which I am the principal investigator:
- Hovon 109: Lenalidomide in addition to chlorambucil and rituximab for first-line elderly patients; phase 1/2
- Hovon 121: Lenalidomide maintenance following induction treatment in Young/fit patients; phase 3
- Hovon 122: Ofatumumab and CAL101 followed by allo-SCT in refractory patients; phase 2
- LLPC: GS9820 (PI3-kinase inhibitor) for relapsed and refractory CLL and (non-) Hodgkin lymphoma; phase 1
 

Faculty
Prof. dr. A.P. Kater MD PhD

Postdocs
Dr. E. Slinger
Dr. S.H. Tonino MD PhD
Dr. G.J.W. van der Windt

PhD Students
F. Brocco
J.A.C. van Bruggen MSc
Z. Chen PhD
M.V. Haselager
T. Hofland MSc
A.C. Leeksma MD
A.W.J. Martens
Y.J. Thus
I. de Weerdt MD

Others
Drs. J. ter Burg
Dr. J. Dubois
Drs. S. Klein
Drs. R. Liu
D.M.P. Luijks
Drs. S. Terpstra
Drs. C. Wijnands

Prof. dr. E. Eldering (Apoptosis regulation in immuno-hematology)

Prof. dr. M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)

Other research related activities
  • Membership of medical or scientific committee, HOVON, CLL
  • Contribution to guidelines and protocols, CLL and MBL treatment
  • Membership of advisory board / Consultant, CEITEC; Central European Institute of Technology, Brno, Czech Republic
  • Membership of advisory board / Consultant, Celgene, Mundipharma
  • Board of directors / Trustees / Supervisory board, Centraal Israelitische ziekenverpleging
  • Membership of editorial board / Editorship, NEDERLANDS TIJDSCHRIFT VOOR HEMATOLOGIE
  • Board of directors / Trustees / Supervisory board, Fonds CIZ/ziekenhuis Amstelland
Current research funding
  • AbbVie B.V.
  • Acerta Pharma B.V.
  • Acerta Pharmaceuticals
  • AMC
  • AMC (Vrijgesteld)
  • AstraZeneca AB R&D Södertälje
  • Bristol-Myers Squibb B.V. (0059)
  • Celgene Corporation
  • Celgene International Il Sàrl
  • Gilead Sciences, Inc.
  • Janssen Research & Development, LLC
  • Johnson & Johnson Shared Services
  • KWF Kankerbestrijding
  • Quintiles B.V.
  • Rijksdienst voor Ondernemend Nederland
  • Stichting AMC Foundation (Vrijgesteld)
  • Stichting Hovon Amsterdam, p/a VUmc
  • ZonMw